Real-World Effectiveness of Golimumab in Ulcerative Colitis: A Pooled Analysis from the Prospective UMBRELLA-IBD Registry in Germany.

ABSTRACT: Background: The efficacy and safety of the anti-TNF inhibitor golimumab in ulcerative colitis (UC) have been demonstrated in pivotal randomized controlled trials (RCTs). However, real-world data are needed to assess its effectiveness and safety in routine clinical practice, where patient populations and treatment settings are more heterogeneous. Methods: This pooled, retrospective-prospective cohort analysis draws on primary data from four IBD registries that contribute UC data to the UMBRELLA-IBD data warehouse: BioColitis, RUN-UC, TARGET-IBD, and VEDO-IBD. Data for each registry were collected across multiple centers under routine clinical care conditions in Germany. Eligible patients had a confirmed diagnosis of UC according to DGVS/ECCO criteria, were ≥18 years of age, an

SUBMITTER: Bokemeyer A 

PROVIDER: S-EPMC12565339 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature